Alexandria T. Phan

Dr. Alexandria T. Phan

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2022 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
EREmma N. Rizen
Emma N. Rizen
APAlexandria T. Phan
Alexandria T. Phan

1 May 2008 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
MKMichelle M. Kim
Michelle M. Kim
PMPaul F. Mansfield
Paul F. Mansfield
PDPrajnan Das
Prajnan Das
NJNora A. Janjan
Nora A. Janjan
BBBrian D. Badgwell
Brian D. Badgwell
SKSunil Krishnan
Sunil Krishnan
Surgery remains the only potentially curative treatment for patients with gastric cancer. Curative surgery, however, can only be performed in a minority of patients who undergo surgical exploration. Even among patients who undergo radical resection, the rates of locoregional recurrence and systemic metastases remain high. In an effort to address these risks and improve the rates of tumor control and overall survival, multiple perioperative and postoperative strategies have been evaluated over the last 3 decades. The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial evaluated a regimen of epirubicin, cisplatin, and 5-fluorouracil (5-FU) given preoperatively and postoperatively compared with surgery alone in patients with esophageal/gastroesophageal and gastric cancers ( 1 x 1 Cunningham, D., Allum, W.H., Stenning, S.P. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11–20 Crossref | PubMed | Scopus (2971) | Google Scholar See all References ) (1) . Although only 42% of patients in the perioperative arm completed all protocol treatment, the perioperative-chemotherapy group had a higher likelihood of overall survival and progression-free survival than the surgery group (p = 0.009 and p < 0.001, respectively). The Intergroup Trial 0116 randomized surgically resected patients to observation vs. postoperative 5-FU, leucovorin, and 45 Gy of radiation therapy ( 2 x 2 Macdonald, J.S., Smalley, S.R., Benedetti, J. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345: 725–730 Crossref | PubMed | Scopus (2391) | Google Scholar See all References ) (2) . Multimodality therapy improved locoregional control and overall survival in gastric cancer patients after resection with microscopically negative margins (R0). Nonetheless, a significant number of patients do not qualify for this therapy because R0 resection can only be achieved in less than 50% of patients ( 3 x 3 Adashek, K., Sanger, J., and Longmire, W.P. Jr. Cancer of the stomach. Review of consecutive ten year intervals. Ann Surg. 1979; 189: 6–10 Crossref | PubMed | Scopus (101) | Google Scholar See all References , 4 x 4 Wanebo, H.J., Kennedy, B.J., Chmiel, J. et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993; 218: 583–592 Crossref | PubMed | Scopus (553) | Google Scholar See all References ).

24 October 2025 in Cancer Research
Verified
Journal Article
Open access
MKMandana Kamgar
Mandana Kamgar
GHGuy Aaron Hobbs
Guy Aaron Hobbs
RDRaven Davidson
Raven Davidson
DDDaniel Dorbin
Daniel Dorbin
JHJuliannie Herrera
Juliannie Herrera
TMThomas McFall
Thomas McFall
Therapies targeting the RAF–MEK–ERK pathway are generally considered to have limited efficacy in KRAS-mutant cancers. However, specific KRAS mutants exhibit distinct behaviors. Notably, KRASG12R pancreatic ductal adenocarcinoma (PDAC) tumors have shown sensitivity to MEK inhibitors (MEKi) in combination with autophagy inhibitors, but a better understanding of the underlying mechanisms is needed to optimize this treatment strategy. Using a systems-level approach, we uncovered a mechanistic explanation for this phenomenon. Due to distinct biophysical properties, KRASG12R had an impaired ability to activate wild-type HRAS and NRAS (WT-RAS) compared with other KRAS mutants, such as KRASG12D. This reduced activation stemmed from the weaker interaction between KRASG12R and guanine exchange factors (SOS), as well as the tumor suppressor neurofibromin (NF1), crucial in regulating WT-RAS activity. The impaired ability to activate WT-RAS led to weaker holistic MAPK signaling in KRASG12R-driven tumors, which conferred increased sensitivity to MEKi. To substantiate the preclinical findings, the utility of MEKi in combination with the autophagy inhibitor hydroxychloroquine was analyzed in patients with KRASG12R-mutated metastatic PDAC. Five of the eight (62.5%) patients treated in first- or second-line settings had a progression-free survival exceeding 6 months. Three patients had impressive disease control: two had stable disease of 11 and 22.7 months, and one achieved a partial response with an 83% decrease in tumor size that lasted for 8.9 months. Overall, this work highlights how systems-based approaches in precision medicine can uncover mechanistic insights to guide the identification of patients with PDAC most likely to benefit from tailored therapeutic strategies. Significance: The unique sensitivity of KRASG12R-mutant cancers to MEK inhibitors offers a critical advancement in understanding MAPK signaling and paving the way for precision-targeted therapies in previously untreatable contexts. See related commentary by Tiriac and Engle, p. 1817 See related article by Burge et al., p. 1854 See related article by Burge et al., p. 1868

20 May 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SYSriram Yennurajalingam
Sriram Yennurajalingam
SFSusan Frisbee-Hume
Susan Frisbee-Hume
MDMarvin Omar Delgado-Guay
Marvin Omar Delgado-Guay
JBJanet Bull
Janet Bull
APAlexandria T. Phan
Alexandria T. Phan
Eduardo BrueraEduardo Bruera
Eduardo Bruera
9002 Background: Cancer-related-fatigue (CRF) is the most common and distressing symptoms in patients with advanced cancer. Currently, there is no standard treatment for CRF. Although corticosteroids have been used in the treatment of CRF, there are no well-powered placebo-controlled trials that used a validated CRF outcome measure. The primary objective of this prospective, randomized, double-blind, placebo-controlled study is to compare the effect of DM versus placebo on CRF. Methods: Advanced cancer patients with fatigue ≥ 4/10 on the Edmonton Symptom Assessment Scale (ESAS) and at least 2 other CRF-related symptoms (pain, nausea, appetite, depression, anxiety or sleep disturbance ≥ 4/10), normal cognition, no infections and hemoglobin ≥ 9 g/L were eligible for enrollment. Patients were randomized to either receive dexamethasone 4 mg orally twice a day for 15 days (primary end point) or matching placebo. The primary outcome was the day 15 change in Functional Assessment of Chronic Illness-Fatigue (FACIT-F) subscale scores. Differences in the group means (normal distribution) were analyzed using the two-sample t-test. Results: In 83 evaluable patients (43 DM and 40 placebo), median age was 60 years, 61% were white, and 53% were female. There was no difference in the demographics and fatigue (FACIT-F subscale) between DM and placebo groups except for sex (p=0.02). The mean (SD) FACIT-F subscores at baseline and at day 15 for DM were 18 (11) and 27 (11) (p<0.001) and for placebo were 21 (9) and 24 (12) (p=0.06), respectively. Mean improvement in FACIT-F subscale was significantly higher in the DM group compared to placebo (9.6 (11) vs. 3.1 (9.7), p=0.005). We found a significant difference in ESAS physical distress (p=0.02), but no differences in ESAS overall symptom distress (p=0.11) and ESAS psychological distress (P=0.88) between DM and placebo. There were insignificantly higher numbers of grade ≥3 toxicities in patients who received DM than in patients who received placebo (20/42 vs. 18/47, p=0.37). Conclusions: Dexamethasone was more effective than placebo in reducing CRF in patients with advanced cancer. Long-term safety studies are needed.

19 May 2021 in Future Oncology
Verified
Journal Article
Open access
NZNicole M Zimmerman
Nicole M Zimmerman
DRDavid Ray
David Ray
NPNicole Princic
Nicole Princic
MMMeghan Moynihan
Meghan Moynihan
CCCallisia Clarke
Callisia Clarke
APAlexandria T. Phan
Alexandria T. Phan
Aim: Machine learning reveals pathways to neuroendocrine tumor (NET) diagnosis. Patients & methods: Patients with NET and age-/gender-matched non-NET controls were retrospectively selected from Mar... Lay abstract We present the novel analytic approach of machine learning using real-world data to describe patient pathways to neuroendocrine tumor (NET) diagnosis. Due to the rarity and presentatio...